Form 4: Arcus Biosciences President Sells Shares

Arcus Biosciences President Juan C. Jaen sold 82,997 shares of common stock for a weighted average price of $24.7069 per share.

Summary

• Juan C. Jaen, President of Arcus Biosciences, Inc. (RCUS), reported the sale of 82,997 shares of the company's common stock.
• The transaction occurred on December 4, 2025.
• The shares were sold at a weighted average price of $24.7069 per share, with individual transaction prices ranging from $24.35 to $25.15.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Jaen on August 8, 2025.
• Following this transaction, Mr. Jaen directly beneficially owns 367,220 shares of common stock and indirectly owns 954,063 shares through a trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sale by a key executive reduces direct ownership, the pre-planned nature under a Rule 10b5-1 plan mitigates significant negative implications, suggesting it's for personal financial management rather than a reaction to new company-specific information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transaction was scheduled in advance and not based on new, non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by investors as it reduces a key executive's direct equity stake in the company.

Risks

• There is a potential for negative investor sentiment if the market interprets the insider sale as a lack of confidence, despite the existence of a Rule 10b5-1 plan.

Industry Context

This Form 4 filing reports a routine insider transaction for a biotechnology company executive. Such filings are common across all industries, including biotech, as executives manage their personal portfolios and liquidity, often through pre-arranged trading plans.

Stakeholder Impact

• Shareholders may observe the reduction in direct insider ownership, which could influence their perception of management's alignment with shareholder interests, though the 10b5-1 plan lessens this concern.

Key Dates

Keywords

Arcus Biosciences, RCUS, insider trading, Form 4, stock sale, executive compensation, 10b5-1 plan, biotechnology